{"Content: ":"N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.[1] In early 2020, in collaboration with NRC the VBI's vaccine\u2014VBI-2900\u2014was developed. According to the company, they have two vaccine candidates\u2014\"enveloped virus-like particle (eVLP)\".[2] VBI-2901 is a \"trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins\". VBI-2902 is a \"monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein\".[2] By March 9, the initial Phase 1/2 study of VBI-2902 was underway.[2][3][4] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.[5] https://www.vbivaccines.com/press-releases/vbi-2902-preclinical-and-challenge-study-data/ This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.","Title":"VBI-2902 - Wikipedia","KeyID":"11194","URL":"https://en.wikipedia.org/wiki/VBI-2902"}